| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neovascularization, Pathologic | 59 | 2019 | 1547 | 6.500 |
Why?
|
| Vascular Endothelial Growth Factor A | 62 | 2019 | 1533 | 5.730 |
Why?
|
| Colorectal Neoplasms | 66 | 2023 | 3578 | 5.620 |
Why?
|
| Angiogenesis Inhibitors | 40 | 2016 | 1248 | 4.640 |
Why?
|
| Colonic Neoplasms | 26 | 2023 | 1390 | 2.200 |
Why?
|
| Antibodies, Monoclonal | 40 | 2016 | 4367 | 2.050 |
Why?
|
| Endothelial Cells | 13 | 2019 | 1048 | 2.000 |
Why?
|
| Neoplasms | 48 | 2021 | 15193 | 1.980 |
Why?
|
| Neoplastic Stem Cells | 8 | 2018 | 1443 | 1.910 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 6 | 2017 | 125 | 1.900 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 13 | 2019 | 355 | 1.810 |
Why?
|
| Receptor, IGF Type 1 | 7 | 2009 | 347 | 1.690 |
Why?
|
| Cell Movement | 24 | 2017 | 2466 | 1.660 |
Why?
|
| Liver Neoplasms | 36 | 2016 | 4557 | 1.470 |
Why?
|
| Liver Neoplasms, Experimental | 8 | 2011 | 196 | 1.350 |
Why?
|
| Endothelium, Vascular | 15 | 2006 | 891 | 1.280 |
Why?
|
| Endothelial Growth Factors | 15 | 2003 | 197 | 1.250 |
Why?
|
| Clinical Trials as Topic | 18 | 2019 | 3719 | 1.240 |
Why?
|
| Neuropilin-2 | 5 | 2011 | 21 | 1.210 |
Why?
|
| Vascular Endothelial Growth Factors | 17 | 2019 | 212 | 1.200 |
Why?
|
| Signal Transduction | 41 | 2019 | 11965 | 1.160 |
Why?
|
| Antineoplastic Agents | 33 | 2022 | 14289 | 1.110 |
Why?
|
| Fluorouracil | 16 | 2016 | 1944 | 1.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 10 | 2013 | 650 | 1.070 |
Why?
|
| Pancreatic Neoplasms | 19 | 2010 | 5061 | 1.070 |
Why?
|
| Neuropilin-1 | 7 | 2008 | 40 | 1.030 |
Why?
|
| Cell Line, Tumor | 47 | 2023 | 14551 | 1.030 |
Why?
|
| ErbB Receptors | 9 | 2022 | 2295 | 1.020 |
Why?
|
| Bevacizumab | 23 | 2019 | 938 | 1.010 |
Why?
|
| Neoplasm Invasiveness | 16 | 2017 | 3981 | 1.000 |
Why?
|
| Gastrointestinal Neoplasms | 5 | 2013 | 600 | 1.000 |
Why?
|
| Juvenile Delinquency | 2 | 2016 | 28 | 0.990 |
Why?
|
| Humans | 220 | 2023 | 261506 | 0.990 |
Why?
|
| Carcinoid Tumor | 4 | 2011 | 280 | 0.980 |
Why?
|
| Lymphokines | 13 | 2003 | 272 | 0.980 |
Why?
|
| Biomedical Research | 6 | 2021 | 806 | 0.970 |
Why?
|
| Drug Resistance, Neoplasm | 20 | 2019 | 5178 | 0.930 |
Why?
|
| Proto-Oncogene Proteins c-met | 6 | 2017 | 419 | 0.920 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2017 | 268 | 0.910 |
Why?
|
| Angiogenesis Inducing Agents | 4 | 2011 | 106 | 0.870 |
Why?
|
| Organoplatinum Compounds | 8 | 2013 | 702 | 0.870 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 7 | 2007 | 661 | 0.840 |
Why?
|
| Medical Oncology | 6 | 2021 | 1423 | 0.830 |
Why?
|
| Neoplasm Metastasis | 19 | 2013 | 5112 | 0.820 |
Why?
|
| Receptor, TIE-2 | 8 | 2016 | 82 | 0.800 |
Why?
|
| Mice, Nude | 25 | 2022 | 4307 | 0.800 |
Why?
|
| Cell Communication | 3 | 2018 | 509 | 0.790 |
Why?
|
| Animals | 79 | 2023 | 59536 | 0.770 |
Why?
|
| Interleukin-1 | 5 | 2004 | 461 | 0.750 |
Why?
|
| Antibodies, Monoclonal, Humanized | 24 | 2013 | 3251 | 0.750 |
Why?
|
| Proto-Oncogene Proteins c-akt | 9 | 2018 | 2054 | 0.750 |
Why?
|
| Adenocarcinoma | 22 | 2017 | 7789 | 0.720 |
Why?
|
| Insulin-Like Growth Factor I | 7 | 2007 | 630 | 0.700 |
Why?
|
| Mice | 57 | 2023 | 34495 | 0.690 |
Why?
|
| Receptors, Cell Surface | 4 | 2008 | 862 | 0.690 |
Why?
|
| Gene Expression Regulation, Neoplastic | 17 | 2016 | 8873 | 0.670 |
Why?
|
| Apoptosis | 24 | 2019 | 7591 | 0.660 |
Why?
|
| HT29 Cells | 10 | 2019 | 159 | 0.640 |
Why?
|
| Cell Survival | 11 | 2022 | 3045 | 0.630 |
Why?
|
| RNA, Small Interfering | 10 | 2019 | 2216 | 0.630 |
Why?
|
| Receptor, ErbB-3 | 1 | 2018 | 122 | 0.630 |
Why?
|
| Publications | 1 | 2018 | 54 | 0.630 |
Why?
|
| Paracrine Communication | 2 | 2017 | 128 | 0.630 |
Why?
|
| ADAM Proteins | 2 | 2016 | 134 | 0.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2019 | 15862 | 0.620 |
Why?
|
| Ethics, Research | 1 | 2018 | 67 | 0.620 |
Why?
|
| Cell Division | 12 | 2010 | 2489 | 0.620 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 4 | 2009 | 272 | 0.610 |
Why?
|
| Masculinity | 1 | 2017 | 2 | 0.610 |
Why?
|
| Nanog Homeobox Protein | 1 | 2017 | 65 | 0.600 |
Why?
|
| Fusobacterium Infections | 1 | 2017 | 28 | 0.600 |
Why?
|
| Research | 2 | 2018 | 415 | 0.600 |
Why?
|
| Chemokine CCL20 | 1 | 2017 | 39 | 0.600 |
Why?
|
| Sex Characteristics | 2 | 2017 | 417 | 0.600 |
Why?
|
| Peer Review, Research | 1 | 2017 | 66 | 0.590 |
Why?
|
| Drugs, Investigational | 2 | 2015 | 135 | 0.590 |
Why?
|
| Fusobacterium nucleatum | 1 | 2017 | 35 | 0.590 |
Why?
|
| Twins | 1 | 2017 | 70 | 0.590 |
Why?
|
| Pericytes | 6 | 2008 | 96 | 0.580 |
Why?
|
| Tumor Cells, Cultured | 18 | 2016 | 5395 | 0.580 |
Why?
|
| Heterosexuality | 1 | 2016 | 11 | 0.560 |
Why?
|
| Homosexuality | 1 | 2016 | 32 | 0.560 |
Why?
|
| Cell Proliferation | 20 | 2023 | 7226 | 0.560 |
Why?
|
| Mothers | 2 | 2016 | 410 | 0.540 |
Why?
|
| Scientific Misconduct | 1 | 2015 | 21 | 0.530 |
Why?
|
| Hedgehog Proteins | 1 | 2018 | 424 | 0.520 |
Why?
|
| Pseudogenes | 1 | 2015 | 81 | 0.520 |
Why?
|
| HCT116 Cells | 8 | 2019 | 348 | 0.510 |
Why?
|
| Functional Laterality | 1 | 2016 | 316 | 0.500 |
Why?
|
| Sexual Behavior | 1 | 2017 | 310 | 0.500 |
Why?
|
| Patients | 1 | 2017 | 245 | 0.490 |
Why?
|
| Transcription Factors | 9 | 2013 | 5270 | 0.490 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 218 | 0.490 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2017 | 973 | 0.490 |
Why?
|
| Carcinoma | 6 | 2008 | 2578 | 0.480 |
Why?
|
| ras Proteins | 2 | 2015 | 770 | 0.480 |
Why?
|
| Angiopoietins | 2 | 2011 | 35 | 0.480 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 3 | 2009 | 107 | 0.470 |
Why?
|
| Reproducibility of Results | 6 | 2018 | 6009 | 0.470 |
Why?
|
| Neoplasm Proteins | 6 | 2017 | 3230 | 0.460 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2012 | 503 | 0.450 |
Why?
|
| Membrane Proteins | 8 | 2013 | 2819 | 0.450 |
Why?
|
| Xenograft Model Antitumor Assays | 14 | 2023 | 3821 | 0.450 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2014 | 607 | 0.450 |
Why?
|
| Monocytes | 1 | 2017 | 788 | 0.450 |
Why?
|
| Angiopoietin-1 | 5 | 2016 | 21 | 0.450 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2020 | 10035 | 0.440 |
Why?
|
| Androgens | 1 | 2016 | 511 | 0.440 |
Why?
|
| Biomarkers, Tumor | 13 | 2016 | 10331 | 0.440 |
Why?
|
| Calcium-Binding Proteins | 2 | 2013 | 545 | 0.440 |
Why?
|
| Semaphorins | 2 | 2009 | 38 | 0.440 |
Why?
|
| Liver | 6 | 2022 | 2961 | 0.440 |
Why?
|
| Protein Kinase Inhibitors | 12 | 2023 | 4757 | 0.440 |
Why?
|
| Language | 1 | 2015 | 309 | 0.430 |
Why?
|
| Wound Healing | 3 | 2010 | 815 | 0.430 |
Why?
|
| Surgeons | 1 | 2019 | 519 | 0.430 |
Why?
|
| Culture Media, Conditioned | 6 | 2018 | 260 | 0.420 |
Why?
|
| Testosterone | 1 | 2017 | 619 | 0.420 |
Why?
|
| Substance-Related Disorders | 1 | 2016 | 524 | 0.410 |
Why?
|
| Platelet-Derived Growth Factor | 3 | 2007 | 157 | 0.410 |
Why?
|
| Cyclooxygenase 2 | 5 | 2019 | 483 | 0.410 |
Why?
|
| Hepatectomy | 11 | 2012 | 1011 | 0.410 |
Why?
|
| Intestinal Neoplasms | 3 | 2010 | 189 | 0.400 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2014 | 665 | 0.400 |
Why?
|
| Macrophages | 1 | 2018 | 1304 | 0.400 |
Why?
|
| Health Personnel | 1 | 2017 | 625 | 0.400 |
Why?
|
| Phosphorylation | 14 | 2016 | 4804 | 0.390 |
Why?
|
| Research Report | 3 | 2018 | 144 | 0.390 |
Why?
|
| Stomach Neoplasms | 7 | 2007 | 2278 | 0.390 |
Why?
|
| Male | 79 | 2020 | 123000 | 0.390 |
Why?
|
| Mesoderm | 4 | 2007 | 404 | 0.380 |
Why?
|
| Carcinogenesis | 1 | 2017 | 1026 | 0.380 |
Why?
|
| Neuroendocrine Tumors | 3 | 2011 | 634 | 0.380 |
Why?
|
| Neuropilins | 2 | 2009 | 14 | 0.380 |
Why?
|
| Mitogen-Activated Protein Kinases | 5 | 2004 | 639 | 0.370 |
Why?
|
| RNA, Messenger | 13 | 2015 | 6150 | 0.370 |
Why?
|
| Drug Delivery Systems | 5 | 2011 | 669 | 0.370 |
Why?
|
| Liver Regeneration | 2 | 2008 | 134 | 0.360 |
Why?
|
| Carcinoma, Hepatocellular | 9 | 2008 | 2027 | 0.360 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2007 | 726 | 0.360 |
Why?
|
| Expert Testimony | 1 | 2010 | 90 | 0.360 |
Why?
|
| Membrane Glycoproteins | 4 | 2003 | 1073 | 0.360 |
Why?
|
| Phenotype | 5 | 2018 | 6295 | 0.350 |
Why?
|
| Transfection | 10 | 2008 | 2944 | 0.350 |
Why?
|
| Receptors, Notch | 1 | 2013 | 383 | 0.350 |
Why?
|
| Catheter Ablation | 8 | 2006 | 620 | 0.350 |
Why?
|
| Research Design | 5 | 2019 | 1544 | 0.350 |
Why?
|
| Exercise | 1 | 2017 | 1183 | 0.340 |
Why?
|
| Colectomy | 4 | 2020 | 288 | 0.340 |
Why?
|
| Suicide, Assisted | 2 | 2019 | 19 | 0.340 |
Why?
|
| Practice Guidelines as Topic | 5 | 2018 | 2403 | 0.340 |
Why?
|
| Female | 76 | 2020 | 141928 | 0.340 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2023 | 1331 | 0.340 |
Why?
|
| Heterografts | 3 | 2018 | 733 | 0.330 |
Why?
|
| Sirolimus | 3 | 2011 | 814 | 0.330 |
Why?
|
| Canada | 3 | 2017 | 429 | 0.330 |
Why?
|
| Nitric Oxide Synthase | 2 | 2006 | 314 | 0.320 |
Why?
|
| Research Personnel | 2 | 2021 | 156 | 0.320 |
Why?
|
| Blotting, Western | 8 | 2016 | 3536 | 0.320 |
Why?
|
| Camptothecin | 6 | 2013 | 517 | 0.320 |
Why?
|
| Transcription, Genetic | 8 | 2008 | 3154 | 0.320 |
Why?
|
| Pyrroles | 4 | 2010 | 576 | 0.320 |
Why?
|
| Quinazolines | 3 | 2018 | 923 | 0.310 |
Why?
|
| Blotting, Northern | 6 | 2007 | 682 | 0.310 |
Why?
|
| Epidermal Growth Factor | 3 | 2004 | 423 | 0.310 |
Why?
|
| Ileal Neoplasms | 1 | 2007 | 47 | 0.310 |
Why?
|
| beta Catenin | 1 | 2011 | 688 | 0.310 |
Why?
|
| Mice, Inbred BALB C | 8 | 2012 | 2314 | 0.300 |
Why?
|
| Epithelium | 2 | 2007 | 720 | 0.300 |
Why?
|
| Fibroblast Growth Factor 2 | 4 | 2005 | 223 | 0.300 |
Why?
|
| Random Allocation | 6 | 2009 | 703 | 0.300 |
Why?
|
| United States | 14 | 2021 | 15433 | 0.300 |
Why?
|
| Neoplasm Transplantation | 7 | 2011 | 1519 | 0.290 |
Why?
|
| Interleukin-8 | 4 | 2004 | 519 | 0.290 |
Why?
|
| Gene Expression | 6 | 2014 | 3570 | 0.290 |
Why?
|
| Disease Progression | 11 | 2019 | 6682 | 0.290 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 3 | 2004 | 215 | 0.290 |
Why?
|
| Nitroarginine | 1 | 2006 | 11 | 0.290 |
Why?
|
| Depression | 1 | 2016 | 1715 | 0.280 |
Why?
|
| Indoles | 4 | 2010 | 1009 | 0.280 |
Why?
|
| Antigens, CD | 2 | 2009 | 1385 | 0.280 |
Why?
|
| Enzyme Activation | 7 | 2018 | 1764 | 0.280 |
Why?
|
| Biopsy | 3 | 2019 | 3443 | 0.280 |
Why?
|
| Muscle Strength | 2 | 2017 | 104 | 0.270 |
Why?
|
| Transplantation, Heterologous | 6 | 2011 | 1082 | 0.270 |
Why?
|
| Body Height | 2 | 2017 | 231 | 0.260 |
Why?
|
| Immunohistochemistry | 13 | 2013 | 7548 | 0.260 |
Why?
|
| Smoking | 2 | 2012 | 2440 | 0.260 |
Why?
|
| Middle Aged | 48 | 2020 | 86204 | 0.260 |
Why?
|
| Periodicals as Topic | 3 | 2019 | 338 | 0.260 |
Why?
|
| Aged | 43 | 2020 | 70117 | 0.260 |
Why?
|
| Adult | 42 | 2022 | 77950 | 0.260 |
Why?
|
| Hepatocyte Growth Factor | 4 | 2006 | 142 | 0.260 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2023 | 371 | 0.260 |
Why?
|
| ADAM17 Protein | 2 | 2016 | 15 | 0.250 |
Why?
|
| Rectal Neoplasms | 6 | 2013 | 1202 | 0.250 |
Why?
|
| Survival Analysis | 16 | 2012 | 9180 | 0.250 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2018 | 3639 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2015 | 2594 | 0.240 |
Why?
|
| Ovarian Neoplasms | 5 | 2011 | 4638 | 0.240 |
Why?
|
| Isoenzymes | 2 | 2003 | 614 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 10 | 2013 | 4975 | 0.240 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2014 | 447 | 0.240 |
Why?
|
| Cell Adhesion | 4 | 2017 | 1008 | 0.240 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2007 | 1489 | 0.240 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2005 | 330 | 0.230 |
Why?
|
| Phthalazines | 2 | 2016 | 253 | 0.230 |
Why?
|
| Cetuximab | 5 | 2016 | 472 | 0.230 |
Why?
|
| Integrin alpha5beta1 | 1 | 2003 | 12 | 0.230 |
Why?
|
| Autocrine Communication | 1 | 2003 | 84 | 0.230 |
Why?
|
| Antimetabolites, Antineoplastic | 5 | 2016 | 1299 | 0.230 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2003 | 45 | 0.230 |
Why?
|
| Genetics, Population | 1 | 2004 | 242 | 0.230 |
Why?
|
| Cell Physiological Phenomena | 1 | 2003 | 24 | 0.220 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2003 | 171 | 0.220 |
Why?
|
| Treatment Outcome | 23 | 2015 | 32848 | 0.220 |
Why?
|
| Organic Chemicals | 1 | 2003 | 113 | 0.220 |
Why?
|
| Drug Synergism | 7 | 2019 | 1313 | 0.220 |
Why?
|
| Capillary Permeability | 1 | 2003 | 114 | 0.220 |
Why?
|
| Up-Regulation | 3 | 2005 | 2450 | 0.220 |
Why?
|
| Aged, 80 and over | 22 | 2019 | 29902 | 0.220 |
Why?
|
| Models, Biological | 7 | 2013 | 3254 | 0.220 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2013 | 2359 | 0.220 |
Why?
|
| Nitric Oxide | 1 | 2006 | 644 | 0.220 |
Why?
|
| Recombinant Proteins | 9 | 2006 | 2927 | 0.210 |
Why?
|
| Phosphatidylinositol 3-Kinases | 6 | 2023 | 1678 | 0.210 |
Why?
|
| Extracellular Space | 1 | 2002 | 132 | 0.210 |
Why?
|
| Postoperative Complications | 5 | 2012 | 5542 | 0.210 |
Why?
|
| Societies, Medical | 2 | 2021 | 1335 | 0.200 |
Why?
|
| Financing, Organized | 1 | 2021 | 21 | 0.200 |
Why?
|
| Integrins | 4 | 2004 | 262 | 0.200 |
Why?
|
| Neovascularization, Physiologic | 4 | 2004 | 345 | 0.200 |
Why?
|
| Right to Die | 2 | 2018 | 5 | 0.200 |
Why?
|
| Disease-Free Survival | 15 | 2020 | 10001 | 0.200 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2013 | 430 | 0.200 |
Why?
|
| Ligands | 4 | 2013 | 995 | 0.200 |
Why?
|
| Transcription Factor AP-1 | 1 | 2002 | 246 | 0.200 |
Why?
|
| Pyridines | 2 | 2010 | 1244 | 0.200 |
Why?
|
| Serrate-Jagged Proteins | 2 | 2013 | 85 | 0.200 |
Why?
|
| Oxidative Stress | 3 | 2019 | 1129 | 0.190 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2002 | 198 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 4 | 2016 | 2330 | 0.190 |
Why?
|
| Disease Models, Animal | 8 | 2015 | 7222 | 0.190 |
Why?
|
| Jagged-1 Protein | 2 | 2013 | 101 | 0.190 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2009 | 1724 | 0.190 |
Why?
|
| Neoplasm Staging | 14 | 2020 | 13658 | 0.190 |
Why?
|
| Self Report | 2 | 2016 | 756 | 0.190 |
Why?
|
| MicroRNAs | 5 | 2015 | 2947 | 0.190 |
Why?
|
| Oligopeptides | 1 | 2003 | 429 | 0.190 |
Why?
|
| Conserved Sequence | 2 | 2012 | 469 | 0.190 |
Why?
|
| Enzyme Inhibitors | 6 | 2007 | 1879 | 0.190 |
Why?
|
| Immunoprecipitation | 3 | 2013 | 591 | 0.190 |
Why?
|
| Coculture Techniques | 2 | 2017 | 626 | 0.180 |
Why?
|
| In Vitro Techniques | 4 | 2013 | 1618 | 0.180 |
Why?
|
| Endpoint Determination | 2 | 2018 | 176 | 0.180 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 6 | 2011 | 376 | 0.180 |
Why?
|
| Genetic Therapy | 3 | 2011 | 1616 | 0.180 |
Why?
|
| Immunoblotting | 3 | 2013 | 886 | 0.180 |
Why?
|
| Liver Cirrhosis | 2 | 2005 | 941 | 0.180 |
Why?
|
| Self Administration | 1 | 2019 | 50 | 0.180 |
Why?
|
| Thymidine Phosphorylase | 3 | 2004 | 23 | 0.180 |
Why?
|
| Surveys and Questionnaires | 3 | 2018 | 5687 | 0.170 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2019 | 23 | 0.170 |
Why?
|
| Vincristine | 1 | 2023 | 1511 | 0.170 |
Why?
|
| Ascorbic Acid | 1 | 2019 | 131 | 0.170 |
Why?
|
| Adolescent | 9 | 2017 | 31252 | 0.170 |
Why?
|
| Protein-Tyrosine Kinases | 5 | 2011 | 1756 | 0.170 |
Why?
|
| Cells, Cultured | 6 | 2011 | 5637 | 0.170 |
Why?
|
| Piperidines | 1 | 2004 | 1035 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 152 | 0.170 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2016 | 1062 | 0.170 |
Why?
|
| Breast Neoplasms | 7 | 2020 | 15694 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2013 | 3890 | 0.160 |
Why?
|
| Colon | 2 | 2020 | 670 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2019 | 64 | 0.160 |
Why?
|
| src-Family Kinases | 3 | 2011 | 478 | 0.160 |
Why?
|
| NF-kappa B | 2 | 2003 | 1549 | 0.160 |
Why?
|
| Neoplasms, Experimental | 3 | 2019 | 750 | 0.160 |
Why?
|
| DNA-Binding Proteins | 5 | 2007 | 4821 | 0.160 |
Why?
|
| Thiophenes | 1 | 2019 | 148 | 0.160 |
Why?
|
| Euthanasia, Active | 1 | 2017 | 6 | 0.160 |
Why?
|
| Professional Practice | 1 | 2018 | 82 | 0.160 |
Why?
|
| Pregnancy | 3 | 2017 | 7573 | 0.160 |
Why?
|
| Self Medication | 1 | 2017 | 23 | 0.160 |
Why?
|
| Treatment Failure | 2 | 2012 | 1391 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor B | 2 | 2008 | 10 | 0.150 |
Why?
|
| Proteins | 3 | 2002 | 1963 | 0.150 |
Why?
|
| Prescriptions | 1 | 2017 | 65 | 0.150 |
Why?
|
| Lymphoma, B-Cell | 1 | 2004 | 895 | 0.150 |
Why?
|
| RNA, Bacterial | 1 | 2017 | 80 | 0.150 |
Why?
|
| Keratins | 2 | 2011 | 330 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2017 | 1538 | 0.150 |
Why?
|
| Macrophage Activation | 1 | 2017 | 148 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 289 | 0.150 |
Why?
|
| Peptide Fragments | 3 | 2013 | 1271 | 0.150 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 208 | 0.140 |
Why?
|
| Malaysia | 1 | 2016 | 20 | 0.140 |
Why?
|
| Repressor Proteins | 2 | 2003 | 1664 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2007 | 4938 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 3 | 2019 | 1077 | 0.140 |
Why?
|
| Intestinal Mucosa | 2 | 2017 | 1081 | 0.140 |
Why?
|
| Empathy | 1 | 2017 | 101 | 0.140 |
Why?
|
| Th17 Cells | 1 | 2017 | 162 | 0.130 |
Why?
|
| Anniversaries and Special Events | 1 | 2015 | 23 | 0.130 |
Why?
|
| Statistics as Topic | 1 | 2017 | 445 | 0.130 |
Why?
|
| Technology, Pharmaceutical | 1 | 2015 | 26 | 0.130 |
Why?
|
| Receptors, Growth Factor | 2 | 2009 | 157 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2017 | 1217 | 0.130 |
Why?
|
| Publication Bias | 1 | 2015 | 38 | 0.130 |
Why?
|
| Young Adult | 5 | 2017 | 21445 | 0.130 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 383 | 0.130 |
Why?
|
| RNA, Antisense | 1 | 2015 | 69 | 0.130 |
Why?
|
| Motor Skills | 1 | 2016 | 107 | 0.130 |
Why?
|
| Students | 1 | 2018 | 324 | 0.130 |
Why?
|
| Interleukin-17 | 1 | 2017 | 250 | 0.130 |
Why?
|
| Publishing | 1 | 2017 | 220 | 0.130 |
Why?
|
| Fingers | 1 | 2016 | 120 | 0.130 |
Why?
|
| Blood Vessels | 2 | 2006 | 217 | 0.130 |
Why?
|
| Urokinase-Type Plasminogen Activator | 2 | 2005 | 136 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2017 | 490 | 0.130 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 356 | 0.130 |
Why?
|
| Prognosis | 14 | 2020 | 21713 | 0.130 |
Why?
|
| Medical Futility | 1 | 2015 | 54 | 0.130 |
Why?
|
| Oregon | 3 | 2019 | 20 | 0.130 |
Why?
|
| Interleukins | 1 | 2017 | 325 | 0.130 |
Why?
|
| Retrospective Studies | 18 | 2020 | 37905 | 0.120 |
Why?
|
| Triazoles | 1 | 2019 | 617 | 0.120 |
Why?
|
| Thrombospondins | 2 | 2004 | 21 | 0.120 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 104 | 0.120 |
Why?
|
| Biomarkers | 3 | 2013 | 5047 | 0.120 |
Why?
|
| DNA, Complementary | 2 | 2007 | 869 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2013 | 852 | 0.120 |
Why?
|
| Attitude to Death | 1 | 2015 | 100 | 0.120 |
Why?
|
| Treatment Refusal | 1 | 2015 | 128 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-yes | 1 | 2013 | 23 | 0.120 |
Why?
|
| Gene Silencing | 2 | 2014 | 837 | 0.120 |
Why?
|
| ATP Citrate (pro-S)-Lyase | 1 | 2013 | 16 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2015 | 233 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 245 | 0.120 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2001 | 1415 | 0.120 |
Why?
|
| Vimentin | 1 | 2014 | 253 | 0.120 |
Why?
|
| Pyrimidines | 5 | 2012 | 3518 | 0.120 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 651 | 0.120 |
Why?
|
| Gene Amplification | 1 | 2016 | 731 | 0.110 |
Why?
|
| Burnout, Professional | 1 | 2017 | 205 | 0.110 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2004 | 177 | 0.110 |
Why?
|
| Cadherins | 2 | 2007 | 660 | 0.110 |
Why?
|
| Internet | 1 | 2018 | 706 | 0.110 |
Why?
|
| Alkaline Phosphatase | 1 | 2013 | 207 | 0.110 |
Why?
|
| Cyclohexanes | 2 | 2003 | 38 | 0.110 |
Why?
|
| Hydroxamic Acids | 1 | 2016 | 442 | 0.110 |
Why?
|
| RNA Interference | 2 | 2014 | 1408 | 0.110 |
Why?
|
| Protein Transport | 2 | 2013 | 734 | 0.110 |
Why?
|
| Obesity | 2 | 2004 | 2884 | 0.110 |
Why?
|
| Niacinamide | 2 | 2016 | 421 | 0.110 |
Why?
|
| Time Factors | 10 | 2019 | 12926 | 0.110 |
Why?
|
| Catechin | 2 | 2002 | 32 | 0.110 |
Why?
|
| Sesquiterpenes | 2 | 2003 | 68 | 0.110 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 2864 | 0.110 |
Why?
|
| Piperazines | 4 | 2016 | 2101 | 0.110 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 208 | 0.110 |
Why?
|
| Mutation | 8 | 2023 | 15179 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2007 | 703 | 0.110 |
Why?
|
| Crime | 1 | 2012 | 31 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 860 | 0.110 |
Why?
|
| Infusions, Intravenous | 3 | 2004 | 1382 | 0.110 |
Why?
|
| Drug Administration Schedule | 5 | 2006 | 3472 | 0.110 |
Why?
|
| Protein Kinases | 2 | 2007 | 874 | 0.110 |
Why?
|
| Angiopoietin-2 | 2 | 2002 | 38 | 0.110 |
Why?
|
| Snail Family Transcription Factors | 1 | 2012 | 120 | 0.110 |
Why?
|
| Growth Substances | 2 | 2003 | 300 | 0.100 |
Why?
|
| Genes, p53 | 2 | 2015 | 1090 | 0.100 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2004 | 334 | 0.100 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2011 | 57 | 0.100 |
Why?
|
| Carcinogenicity Tests | 1 | 2011 | 70 | 0.100 |
Why?
|
| Heparin | 2 | 2019 | 360 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2015 | 498 | 0.100 |
Why?
|
| Cytidine Deaminase | 1 | 2011 | 83 | 0.100 |
Why?
|
| Cell Growth Processes | 3 | 2009 | 342 | 0.100 |
Why?
|
| Collagen | 3 | 2006 | 752 | 0.100 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 103 | 0.100 |
Why?
|
| Survival Rate | 8 | 2020 | 12221 | 0.100 |
Why?
|
| S100 Proteins | 1 | 2011 | 181 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 2 | 2015 | 577 | 0.100 |
Why?
|
| Morbidity | 1 | 2012 | 397 | 0.100 |
Why?
|
| Phenylurea Compounds | 2 | 2016 | 580 | 0.100 |
Why?
|
| Genetic Engineering | 2 | 2010 | 288 | 0.100 |
Why?
|
| Yin-Yang | 1 | 2010 | 4 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 792 | 0.100 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2013 | 323 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2008 | 80 | 0.100 |
Why?
|
| Tissue Banks | 1 | 2010 | 55 | 0.090 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 144 | 0.090 |
Why?
|
| Protein Stability | 1 | 2011 | 370 | 0.090 |
Why?
|
| Liposomes | 2 | 2014 | 684 | 0.090 |
Why?
|
| Combined Modality Therapy | 10 | 2009 | 8865 | 0.090 |
Why?
|
| Nanoparticles | 2 | 2014 | 554 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2006 | 1555 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 2 | 2005 | 1487 | 0.090 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 488 | 0.090 |
Why?
|
| Terminal Care | 1 | 2015 | 447 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1249 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2023 | 1546 | 0.090 |
Why?
|
| Cell Hypoxia | 2 | 2008 | 328 | 0.090 |
Why?
|
| Appendiceal Neoplasms | 1 | 2012 | 234 | 0.090 |
Why?
|
| Endostatins | 3 | 2004 | 48 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 2 | 2009 | 1491 | 0.090 |
Why?
|
| Decision Making | 1 | 2017 | 1287 | 0.090 |
Why?
|
| Reactive Oxygen Species | 3 | 2019 | 987 | 0.090 |
Why?
|
| Nuclear Proteins | 3 | 2013 | 3343 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 2 | 2008 | 1130 | 0.090 |
Why?
|
| Microcirculation | 3 | 2005 | 200 | 0.090 |
Why?
|
| Adenosine Triphosphate | 1 | 2011 | 571 | 0.090 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2007 | 448 | 0.090 |
Why?
|
| AC133 Antigen | 1 | 2009 | 110 | 0.090 |
Why?
|
| Extracellular Matrix | 2 | 2003 | 554 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 195 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 1870 | 0.080 |
Why?
|
| Imatinib Mesylate | 3 | 2008 | 1665 | 0.080 |
Why?
|
| Observer Variation | 1 | 2010 | 671 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2008 | 30 | 0.080 |
Why?
|
| Karyotyping | 1 | 2010 | 1022 | 0.080 |
Why?
|
| Pregnancy Proteins | 1 | 2008 | 44 | 0.080 |
Why?
|
| Placenta Growth Factor | 1 | 2008 | 35 | 0.080 |
Why?
|
| Chromosome Aberrations | 2 | 2007 | 1960 | 0.080 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2006 | 157 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 1270 | 0.080 |
Why?
|
| Endoglin | 1 | 2008 | 43 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2012 | 5539 | 0.080 |
Why?
|
| Half-Life | 1 | 2008 | 259 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 918 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2012 | 4549 | 0.080 |
Why?
|
| Injections, Intraperitoneal | 1 | 2008 | 197 | 0.080 |
Why?
|
| Hyaluronan Receptors | 1 | 2009 | 249 | 0.080 |
Why?
|
| Prostatic Neoplasms | 4 | 2011 | 5767 | 0.080 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 14889 | 0.080 |
Why?
|
| Dihydroergotamine | 1 | 1987 | 10 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 993 | 0.080 |
Why?
|
| Benzamides | 3 | 2008 | 1832 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2008 | 105 | 0.080 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 1656 | 0.080 |
Why?
|
| Spasm | 1 | 1987 | 59 | 0.080 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2007 | 132 | 0.080 |
Why?
|
| Cell Nucleus | 3 | 2013 | 1620 | 0.080 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2007 | 104 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 1209 | 0.070 |
Why?
|
| Vasoconstriction | 1 | 1987 | 104 | 0.070 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2014 | 211 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 259 | 0.070 |
Why?
|
| Proportional Hazards Models | 6 | 2020 | 4988 | 0.070 |
Why?
|
| Patient Selection | 1 | 2014 | 2055 | 0.070 |
Why?
|
| Mice, Transgenic | 2 | 2005 | 4143 | 0.070 |
Why?
|
| Spindle Apparatus | 1 | 2006 | 93 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2007 | 280 | 0.070 |
Why?
|
| Serotonin | 1 | 2007 | 264 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2004 | 200 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2008 | 11538 | 0.070 |
Why?
|
| Genotype | 2 | 2012 | 4109 | 0.070 |
Why?
|
| Amiloride | 1 | 2005 | 47 | 0.070 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 4971 | 0.070 |
Why?
|
| Gene Expression Regulation | 4 | 2004 | 4053 | 0.070 |
Why?
|
| Deoxycytidine | 3 | 2009 | 1353 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2007 | 332 | 0.070 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2006 | 159 | 0.070 |
Why?
|
| Tomography, Spiral Computed | 1 | 2006 | 133 | 0.070 |
Why?
|
| Peptides | 2 | 2009 | 1479 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2009 | 747 | 0.070 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2005 | 66 | 0.060 |
Why?
|
| Cloning, Molecular | 2 | 2004 | 1213 | 0.060 |
Why?
|
| DNA Damage | 1 | 2013 | 1954 | 0.060 |
Why?
|
| Precision Medicine | 1 | 2012 | 1154 | 0.060 |
Why?
|
| Endothelium | 2 | 2022 | 158 | 0.060 |
Why?
|
| Antigens, CD34 | 1 | 2006 | 593 | 0.060 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2004 | 53 | 0.060 |
Why?
|
| Databases, Factual | 3 | 2022 | 2218 | 0.060 |
Why?
|
| Thiazoles | 1 | 2009 | 726 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2012 | 2358 | 0.060 |
Why?
|
| Leucovorin | 3 | 2009 | 332 | 0.060 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2004 | 15 | 0.060 |
Why?
|
| Capillaries | 1 | 2004 | 99 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 3552 | 0.060 |
Why?
|
| Cell Line | 1 | 2012 | 5114 | 0.060 |
Why?
|
| DNA Primers | 2 | 2008 | 1399 | 0.060 |
Why?
|
| Mesentery | 1 | 2004 | 72 | 0.060 |
Why?
|
| Amino Acid Sequence | 4 | 2013 | 4233 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 2 | 2004 | 1290 | 0.060 |
Why?
|
| Dasatinib | 2 | 2023 | 862 | 0.060 |
Why?
|
| Sarcoma | 2 | 2006 | 1725 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2008 | 2326 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8223 | 0.060 |
Why?
|
| Herpesvirus 1, Human | 1 | 2004 | 113 | 0.060 |
Why?
|
| Liver Transplantation | 2 | 2003 | 1112 | 0.060 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 2265 | 0.060 |
Why?
|
| Mixed Function Oxygenases | 1 | 2003 | 64 | 0.060 |
Why?
|
| Intracellular Membranes | 1 | 2003 | 108 | 0.060 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2004 | 85 | 0.060 |
Why?
|
| Spiro Compounds | 1 | 2003 | 58 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2012 | 2086 | 0.060 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2004 | 196 | 0.060 |
Why?
|
| Genes, src | 1 | 2023 | 27 | 0.060 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2004 | 109 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2008 | 451 | 0.060 |
Why?
|
| Neoplastic Processes | 1 | 2003 | 15 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2007 | 1439 | 0.060 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2003 | 32 | 0.060 |
Why?
|
| Propionates | 1 | 2003 | 71 | 0.060 |
Why?
|
| Portal Vein | 2 | 2002 | 355 | 0.060 |
Why?
|
| Forecasting | 2 | 2019 | 694 | 0.050 |
Why?
|
| Diathermy | 1 | 2002 | 8 | 0.050 |
Why?
|
| Dinoprostone | 2 | 2019 | 208 | 0.050 |
Why?
|
| Kidney Neoplasms | 2 | 2008 | 3022 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 334 | 0.050 |
Why?
|
| Sarcoma, Ewing | 1 | 2006 | 406 | 0.050 |
Why?
|
| Ephrin-B3 | 1 | 2002 | 5 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2007 | 574 | 0.050 |
Why?
|
| Metalloendopeptidases | 1 | 2003 | 170 | 0.050 |
Why?
|
| Ephrin-B2 | 1 | 2002 | 15 | 0.050 |
Why?
|
| Receptors, Eph Family | 1 | 2002 | 19 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2004 | 699 | 0.050 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2004 | 167 | 0.050 |
Why?
|
| Receptor, EphB4 | 1 | 2002 | 27 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 1037 | 0.050 |
Why?
|
| Gallbladder Neoplasms | 1 | 2004 | 245 | 0.050 |
Why?
|
| Beverages | 1 | 2002 | 105 | 0.050 |
Why?
|
| Drug Design | 1 | 2004 | 375 | 0.050 |
Why?
|
| Anal Canal | 1 | 2003 | 238 | 0.050 |
Why?
|
| Transglutaminases | 1 | 2002 | 99 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 3 | 2005 | 3101 | 0.050 |
Why?
|
| eIF-2 Kinase | 1 | 2002 | 164 | 0.050 |
Why?
|
| Capecitabine | 3 | 2009 | 388 | 0.050 |
Why?
|
| Risk Assessment | 4 | 2009 | 6869 | 0.050 |
Why?
|
| Risk Factors | 4 | 2012 | 17523 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2002 | 611 | 0.050 |
Why?
|
| Virus Replication | 1 | 2004 | 709 | 0.050 |
Why?
|
| Viruses | 1 | 2002 | 159 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2003 | 604 | 0.050 |
Why?
|
| Base Sequence | 3 | 2013 | 4917 | 0.050 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2003 | 275 | 0.050 |
Why?
|
| Pyridones | 1 | 2023 | 348 | 0.050 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2002 | 292 | 0.050 |
Why?
|
| Plant Extracts | 1 | 2002 | 215 | 0.050 |
Why?
|
| Leiomyosarcoma | 1 | 2002 | 223 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 2232 | 0.050 |
Why?
|
| Isomerism | 1 | 2019 | 63 | 0.050 |
Why?
|
| Washington | 1 | 2019 | 70 | 0.040 |
Why?
|
| Pancreas | 1 | 2003 | 718 | 0.040 |
Why?
|
| Down-Regulation | 3 | 2013 | 2074 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2013 | 6089 | 0.040 |
Why?
|
| Drug Approval | 1 | 2020 | 178 | 0.040 |
Why?
|
| Stem Cells | 1 | 2006 | 1213 | 0.040 |
Why?
|
| Bile Duct Neoplasms | 1 | 2004 | 493 | 0.040 |
Why?
|
| Protein Binding | 2 | 2005 | 3438 | 0.040 |
Why?
|
| Cholangiocarcinoma | 1 | 2004 | 493 | 0.040 |
Why?
|
| Prospective Studies | 5 | 2008 | 12873 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2005 | 2488 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2003 | 803 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2019 | 54 | 0.040 |
Why?
|
| Rats | 4 | 2013 | 6086 | 0.040 |
Why?
|
| Rhabdomyosarcoma | 1 | 2002 | 341 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 2003 | 889 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2005 | 1555 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2006 | 1818 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2002 | 848 | 0.040 |
Why?
|
| Luciferases | 2 | 2012 | 445 | 0.040 |
Why?
|
| Cytokines | 2 | 2009 | 2809 | 0.040 |
Why?
|
| Binding Sites | 1 | 2002 | 2171 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2003 | 2292 | 0.040 |
Why?
|
| Probability | 3 | 2004 | 866 | 0.040 |
Why?
|
| Extracellular Vesicles | 1 | 2019 | 135 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 6207 | 0.040 |
Why?
|
| Antibodies | 2 | 2015 | 838 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2004 | 821 | 0.040 |
Why?
|
| Embolization, Therapeutic | 1 | 2002 | 551 | 0.040 |
Why?
|
| Death | 1 | 2018 | 119 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2004 | 2203 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2004 | 1471 | 0.030 |
Why?
|
| Alpha-Amanitin | 1 | 2015 | 5 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2004 | 1823 | 0.030 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2015 | 35 | 0.030 |
Why?
|
| Brachytherapy | 1 | 2002 | 977 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2014 | 3033 | 0.030 |
Why?
|
| Cohort Studies | 4 | 2016 | 9244 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2002 | 3005 | 0.030 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2002 | 882 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2007 | 131 | 0.030 |
Why?
|
| RNA Polymerase II | 1 | 2015 | 182 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2007 | 460 | 0.030 |
Why?
|
| Early Detection of Cancer | 2 | 2012 | 1258 | 0.030 |
Why?
|
| Cell Cycle Proteins | 3 | 2013 | 2045 | 0.030 |
Why?
|
| Antigens, Neoplasm | 2 | 2015 | 1506 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2015 | 274 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2015 | 303 | 0.030 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2016 | 224 | 0.030 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2013 | 49 | 0.030 |
Why?
|
| Genes, bcl-2 | 2 | 2006 | 166 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2013 | 77 | 0.030 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2013 | 126 | 0.030 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2013 | 27 | 0.030 |
Why?
|
| Preoperative Care | 3 | 2006 | 1529 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2012 | 60 | 0.030 |
Why?
|
| Quinolines | 1 | 2016 | 383 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2014 | 333 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 278 | 0.030 |
Why?
|
| APOBEC-3G Deaminase | 1 | 2011 | 6 | 0.030 |
Why?
|
| Karyopherins | 1 | 2013 | 136 | 0.030 |
Why?
|
| Ki-67 Antigen | 2 | 2006 | 666 | 0.030 |
Why?
|
| Sex Factors | 2 | 2008 | 2139 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2014 | 467 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 829 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2015 | 279 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 745 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2013 | 997 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2016 | 479 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 2014 | 716 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 252 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2011 | 289 | 0.020 |
Why?
|
| Rectum | 1 | 2013 | 467 | 0.020 |
Why?
|
| Haplotypes | 1 | 2013 | 856 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2014 | 470 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 2170 | 0.020 |
Why?
|
| Hypoxia | 2 | 2005 | 443 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2012 | 6100 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 256 | 0.020 |
Why?
|
| Microspheres | 1 | 2011 | 210 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 5319 | 0.020 |
Why?
|
| Data Collection | 1 | 2013 | 620 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2012 | 798 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2015 | 1442 | 0.020 |
Why?
|
| Health Policy | 1 | 2012 | 291 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 1085 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2005 | 7551 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 2316 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2012 | 4844 | 0.020 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2009 | 27 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2002 | 621 | 0.020 |
Why?
|
| Cocarcinogenesis | 1 | 2008 | 50 | 0.020 |
Why?
|
| Glycolysis | 1 | 2011 | 519 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 2483 | 0.020 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2009 | 129 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2005 | 4654 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2007 | 62 | 0.020 |
Why?
|
| Skin | 1 | 2013 | 1259 | 0.020 |
Why?
|
| Phlebitis | 1 | 1987 | 8 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 1987 | 56 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 1987 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2008 | 153 | 0.020 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1987 | 140 | 0.020 |
Why?
|
| T-Lymphoma Invasion and Metastasis-inducing Protein 1 | 1 | 2006 | 24 | 0.020 |
Why?
|
| DNA Adducts | 1 | 2007 | 210 | 0.020 |
Why?
|
| DNA, Antisense | 1 | 2006 | 42 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2012 | 686 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2004 | 4298 | 0.020 |
Why?
|
| Anoikis | 1 | 2006 | 63 | 0.020 |
Why?
|
| Homeostasis | 1 | 2011 | 950 | 0.020 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2006 | 34 | 0.020 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2006 | 107 | 0.020 |
Why?
|
| Laminin | 1 | 2006 | 194 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 177 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 5159 | 0.020 |
Why?
|
| Digestive System | 1 | 2006 | 114 | 0.020 |
Why?
|
| Gastrostomy | 1 | 1987 | 180 | 0.020 |
Why?
|
| Digestive System Neoplasms | 1 | 2006 | 82 | 0.020 |
Why?
|
| Semaphorin-3A | 1 | 2005 | 2 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2006 | 259 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2005 | 224 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2006 | 222 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2008 | 1053 | 0.020 |
Why?
|
| Autoradiography | 1 | 2005 | 132 | 0.020 |
Why?
|
| Cobalt | 1 | 2005 | 55 | 0.020 |
Why?
|
| Group IV Phospholipases A2 | 1 | 2004 | 3 | 0.020 |
Why?
|
| Pancreatectomy | 1 | 2009 | 652 | 0.020 |
Why?
|
| Phospholipases A2 | 1 | 2004 | 43 | 0.020 |
Why?
|
| Allantois | 1 | 2004 | 6 | 0.020 |
Why?
|
| Phospholipases A | 1 | 2004 | 52 | 0.020 |
Why?
|
| Chorion | 1 | 2004 | 18 | 0.020 |
Why?
|
| Indomethacin | 1 | 2004 | 91 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2004 | 300 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 1946 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2006 | 621 | 0.020 |
Why?
|
| Celecoxib | 1 | 2004 | 200 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2006 | 264 | 0.020 |
Why?
|
| Peptide Library | 1 | 2004 | 158 | 0.020 |
Why?
|
| Chickens | 1 | 2004 | 523 | 0.010 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2006 | 262 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2004 | 392 | 0.010 |
Why?
|
| Transcription Factor AP-2 | 1 | 2004 | 79 | 0.010 |
Why?
|
| Antigens | 1 | 2004 | 292 | 0.010 |
Why?
|
| Leukemia | 1 | 2012 | 1635 | 0.010 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2005 | 518 | 0.010 |
Why?
|
| Recurrence | 1 | 2012 | 4758 | 0.010 |
Why?
|
| France | 1 | 2003 | 108 | 0.010 |
Why?
|
| Italy | 1 | 2004 | 236 | 0.010 |
Why?
|
| RNA, Catalytic | 1 | 2003 | 37 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 359 | 0.010 |
Why?
|
| Japan | 1 | 2003 | 227 | 0.010 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2006 | 297 | 0.010 |
Why?
|
| Collagen Type XVIII | 1 | 2002 | 17 | 0.010 |
Why?
|
| Immune System | 1 | 2004 | 279 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2006 | 429 | 0.010 |
Why?
|
| Tumor Protein p73 | 1 | 2002 | 105 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 842 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 2002 | 132 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2002 | 115 | 0.010 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2002 | 44 | 0.010 |
Why?
|
| E-Selectin | 1 | 2002 | 103 | 0.010 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2002 | 94 | 0.010 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2002 | 10 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2004 | 652 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 769 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2002 | 226 | 0.010 |
Why?
|
| Ploidies | 1 | 2002 | 248 | 0.010 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2004 | 334 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 121 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 702 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 2004 | 309 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 2003 | 271 | 0.010 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2006 | 690 | 0.010 |
Why?
|
| Lasers | 1 | 2002 | 198 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2002 | 266 | 0.010 |
Why?
|
| Tyrosine | 1 | 2003 | 498 | 0.010 |
Why?
|
| Staurosporine | 1 | 2002 | 143 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2002 | 314 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 6942 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2002 | 471 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2002 | 310 | 0.010 |
Why?
|
| E2F1 Transcription Factor | 1 | 2002 | 206 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 3441 | 0.010 |
Why?
|
| Folic Acid | 1 | 2003 | 349 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 205 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 242 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2004 | 850 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 521 | 0.010 |
Why?
|
| Hepatitis B | 1 | 2003 | 258 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2002 | 875 | 0.010 |
Why?
|
| fas Receptor | 1 | 2002 | 185 | 0.010 |
Why?
|
| Intestine, Small | 1 | 2004 | 499 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2004 | 1021 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2002 | 396 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 2231 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2002 | 344 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2004 | 1544 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 1363 | 0.010 |
Why?
|
| Caspases | 1 | 2002 | 661 | 0.010 |
Why?
|
| DNA Repair | 1 | 2007 | 1872 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2004 | 1732 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 980 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 2049 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2006 | 1863 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 1323 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 1064 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2005 | 1121 | 0.010 |
Why?
|
| Chromatin | 1 | 2004 | 942 | 0.010 |
Why?
|
| Hepatitis C | 1 | 2003 | 524 | 0.010 |
Why?
|
| Graft Survival | 1 | 2002 | 1062 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2005 | 1682 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2014 | 16273 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2002 | 1869 | 0.010 |
Why?
|
| Adenoma | 1 | 2003 | 716 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2003 | 1459 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 2307 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2002 | 1152 | 0.010 |
Why?
|
| Age Factors | 1 | 2006 | 5377 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2002 | 1226 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 2315 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2004 | 3842 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 1493 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2002 | 1823 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 5710 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 2022 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 5673 | 0.010 |
Why?
|
| Child | 1 | 2014 | 29154 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 4892 | 0.010 |
Why?
|
| Texas | 1 | 2004 | 6311 | 0.010 |
Why?
|
| Absorption | 1 | 1987 | 81 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1987 | 410 | 0.000 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1987 | 70 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2002 | 7702 | 0.000 |
Why?
|
| Amino Acids | 1 | 1987 | 728 | 0.000 |
Why?
|
| Glucose | 1 | 1987 | 1248 | 0.000 |
Why?
|